Pedro R. Lowenstein

Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.

Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective.

Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection.

Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types.

Dendritic cells and immune responses in the central nervous system.

Progress and challenges in viral vector-mediated gene transfer to the brain.

Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane.

Use of recombinant adenovirus for gene transfer into the rat brain. Evaluation of gene transfer efficiency, toxicity, and inflammatory and immune reactions.

Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression.

Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty.

Gene therapy for liver transplantation using adenoviral vectors: CD40-CD154 blockade by gene transfer of CD40Ig protects rat livers from cold ischemia and reperfusion injury.

Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells.

Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects.

Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model.

The Collaborative Cross, a community resource for the genetic analysis of complex traits.

Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression.

Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses.

The case for immunosuppression in clinical gene transfer.

Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence.

Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.

Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Platelets mediate cytotoxic T lymphocyte-induced liver damage.

Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses.

Gene therapy and targeted toxins for glioma.

Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain.

Rapid upregulation of interferon-regulated and chemokine mRNAs upon injection of 108 international units, but not lower doses, of adenoviral vectors into the brain.

Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells.

In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain.

Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors.

Adenoviral-mediated gene transfer into the canine brain in vivo.

Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.

Efficacy of nonviral gene transfer in the canine brain.

Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter.

One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.

Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses.

Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.

Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.

Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells.

Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain.

In vivo polarization of IFN-gamma at Kupfer and non-Kupfer immunological synapses during the clearance of virally infected brain cells.

Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.

High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.

Turning the gene tap off; implications of regulating gene expression for cancer therapeutics.

Gene delivery to the nervous system.

Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.

Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators.

With a little help from my f(X)riends!: the basis of Ad5-mediated transduction of the liver revealed.

CD20, CD3, and CD40 ligand microclusters segregate three-dimensionally in vivo at B-cell-T-cell immunological synapses after viral immunity in primate brain.

T cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury.

Clinical trials in gene therapy: ethics of informed consent and the future of experimental medicine.

A call for physiopathological ethics.

Gene transfer into neural cells in vitro using adenoviral vectors.

Crossing the rubicon.

HMGB1 mediates endogenous TLR2 activation and brain tumor regression.

Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.

Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells.

Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.

Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials.

Gene therapy continues to make progress: clinical and regulatory perspectives.

Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?

Risk in clinical research: size matters!

Gene transfer into rat brain using adenoviral vectors.

Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy.

A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.

Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.

Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology.

Cancer vaccines in glioma: how to balance the challenges of small trials, efficiency, and potential adverse events.

Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.

Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

AAV6-mediated gene silencing fALS short.

Gene therapy and targeted toxins for glioma.

Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.

Moving forward toward a cure for Parkinson's: neuropathology of the nigrostriatal pathway determines the location of growth factor delivery.

Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.

Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.

Identification and visualization of CD8+ T cell mediated IFN-γ signaling in target cells during an antiviral immune response in the brain.

B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.

Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cells.

Pushing the limits of glioma resection using electrophysiologic brain mapping.

Cytotoxic immunological synapses do not restrict the action of interferon-γ to antigenic target cells.

Gene therapy for brain tumors: basic developments and clinical implementation.

Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial.

Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.

Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.

Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.

Progress in gene therapy for neurological disorders.

Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma.

Neuro-oncology: The long and winding road--gene therapy for glioma.

Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials.

Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.

Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.

Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H.

Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM.

The value of EGFRvIII as the target for glioma vaccines.

Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier!

Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.

Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.

Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.

Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.

Glioma trials and viral tribulations: can anything be concluded from non-controlled trials?